Repertoire Genesis Overview

  • Founded
  • 2014
Founded
  • Status
  • Private
  • Employees
  • 4
Employees
  • Latest Deal Type
  • Series C
  • Latest Deal Amount
  • $2.67M
Latest Deal Amount
  • Investors
  • 2

Repertoire Genesis General Information

Description

Developer of anti-cancer drugs designed for immune checkpoint blockers and cancer immune therapy. The company's products are T cell receptor (TCR) or B cell receptor (BCR) repertoire analysis that is based on unbiased gene amplification technology and bioinformatics, enabling healthcare providers to offer diagnostic therapies based on immune diversity analysis.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Primary Office
  • Saito Bioincubator 402
  • 7-7-15 Saito-asagi, Ibaraki-shi
  • Osaka, 567-0085
  • Japan
+81 000-000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Repertoire Genesis Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC (Series C) 01-Aug-2017 $2.67M 00.00 Completed Generating Revenue
2. Early Stage VC (Series B) 27-Jul-2016 00.000 00.000 Completed Startup
1. Early Stage VC (Series A) 21-Nov-2014 $1.76M $1.76M Completed Product Development
To view Repertoire Genesis’s complete valuation and funding history, request access »

Repertoire Genesis Executive Team (9)

Name Title Board Seat Contact Info
Ryuji Suzuki MD Co-Founder, Chief Executive Officer & Chairman
Eiichi Yamaguchi President & Chief Operating Officer
Tetsuya Maruyama Senior Corporate Officer & Board Member
Kazutaka Kitaura Co-Founder & Corporate Officer
Takaji Matsutani Co-Founder & Corporate Officer
You’re viewing 5 of 9 executive team members. Get the full list »

Repertoire Genesis Board Members (9)

Name Representing Role Since
Atsushi Usami Ph.D The University of Tokyo Edge Capital Board Member 000 0000
Masahiro Kanamaru Self Board Member 000 0000
Masuo Ichikawa Repertoire Genesis Managing Corporate Officer & Board Member 000 0000
Ryuji Suzuki MD Repertoire Genesis Co-Founder, Chief Executive Officer & Chairman 000 0000
Tetsuya Maruyama Repertoire Genesis Senior Corporate Officer & Board Member 000 0000
You’re viewing 5 of 9 board members. Get the full list »

Repertoire Genesis Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Repertoire Genesis Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Beyond Next Ventures Venture Capital Minority 000 0000 000000 0
The University of Tokyo Edge Capital Venture Capital Minority 000 0000 000000 0
To view Repertoire Genesis’s complete investors history, request access »